Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Maxime Bergere"'
1
Abstract 2871: The Nanoprimer: a nanoparticle designed to transiently occupy the mononuclear phagocytic system in order to increase nanomedicine-based treatments efficacy
Autor: Audrey Darmon, Marion Paolini, Oceane Jibault, Maxime Bergere, Nell R M Saunders, Julie Devalliere, Matthieu Germain, Francis Mpambani, Laurence Poul, Robert Langer
Publikováno v: Cancer Research. 80:2871-2871
Introduction: Most nanomedicines are currently limited in their efficacy due to a sub-optimal biodistribution/accumulation in the target tissues. A large part of the administered dose remains useless due to the high rate of clearance by the mononucle
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71ecff2e31e6d46b597d6cdbe9989043
https://doi.org/10.1158/1538-7445.am2020-2871
Zobrazit plný text záznamu
2
Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile
Autor: Maxime Bergere, Agnès Pottier, Laurent Levy, Matthieu Germain, Marie-Edith Meyre, Francis Mpambani, Marion Paolini, Laurence Poul, Céline Berjaud
Publikováno v: Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Many therapeutic agents offer a low useful dose (dose responsible for efficacy)/useless dose (dose eliminated or responsible for toxicity) ratio, mainly due to the fact that therapeutic agents must ensure in one single object all the functions requir
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cff1c0c3c1ed10d510bdbb6f493cba9
http://europepmc.org/articles/PMC5859131
Zobrazit plný text záznamu
3
Abstract 3613: Mononuclear phagocytic system occupancy to increase nanomedicines based treatment efficacy
Autor: Maxime Bergere, Marion Paolini, Francis Mpambani, Oceane Jibault, Laurence Poul, Matthieu Germain, Audrey Darmon, Julie Devalliere
Publikováno v: Cancer Research. 79:3613-3613
Introduction: To efficiently deliver treatment, nanomedicines must exhibit sufficient blood bioavailability for further accumulation at the target site. So far, a large part of the administered dose remains useless due to the high rate of clearance b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::071bd261ab56cc801e072b7056ca30d6
https://doi.org/10.1158/1538-7445.am2019-3613
Zobrazit plný text záznamu
4
Abstract LB-072: Redefine nanomedicine products bioavailability to improve anti-tumor efficacy
Autor: Laurent Levy, Francis Mpambani, Laurence Poul, Marie-Edith Meyre, Agnès Pottier, Matthieu Germain, Marion Paolini, Maxime Bergere
Publikováno v: Cancer Research. 78:LB-072
Introduction: The benefit of a nanomedicine is due to its bioavailability, its intrinsic efficacy balanced with its toxicity profile. The nanomedicine should exhibit sufficient blood bioavailability for efficient accumulation at the target site. So f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0be0751ca0e56dfc2268dd086fbcc52e
https://doi.org/10.1158/1538-7445.am2018-lb-072
Zobrazit plný text záznamu
6
Abstract 4581: Combination treatment of orexin-A and NAB-paclitaxel in pancreas cancer: in vitro and in vivo studies
Autor: Pascal Nicole, Stephanie Dayot, Alain Couvineau, Valérie Gratio, Anne Couvelard, Maxime Bergere, Thierry Voisin, Dina Plaut
Publikováno v: Cancer Research. 76:4581-4581
Orexin-A (OxA) and orexin-B (OxB) are hypothalamic peptides involved in the sleep/wake control which interact with two class A GPCR, OX1R and OX2R. We have demonstrated that OX1R was highly expressed in digestive cancers including cancer of colon1, p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc33fb96988c5710fa54ce475049d710
https://doi.org/10.1158/1538-7445.am2016-4581
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje